share_log

翰森製藥:根據首次公開發售後受限制股份單位計劃授出受限制股份單位

HANSOH PHARMA: GRANT OF RESTRICTED SHARE UNITS UNDERTHE POST-IPO RSU SCHEME

HKEX ·  Jun 27, 2024 22:27

Summary by Moomoo AI

翰森製藥集團有限公司於2024年6月27日宣布,根據2019年5月27日採納的首次公開發售後受限制股份單位計劃,向616名承授人授出共11,397,590股的受限制股份單位。其中包括2名公司董事,執行董事孫遠女士獲授1,300,000股,執行董事呂愛鋒博士獲授291,850股,以及614名公司員工。該受限制股份單位的購買價為每股3.379港元,而授出日期當天的收市價為每股16.48港元。受限制股份單位的歸屬期分為三年,並設有表現目標和退扣機制。該計劃不涉及新股發行,且授出無需獲得股東批准。
翰森製藥集團有限公司於2024年6月27日宣布,根據2019年5月27日採納的首次公開發售後受限制股份單位計劃,向616名承授人授出共11,397,590股的受限制股份單位。其中包括2名公司董事,執行董事孫遠女士獲授1,300,000股,執行董事呂愛鋒博士獲授291,850股,以及614名公司員工。該受限制股份單位的購買價為每股3.379港元,而授出日期當天的收市價為每股16.48港元。受限制股份單位的歸屬期分為三年,並設有表現目標和退扣機制。該計劃不涉及新股發行,且授出無需獲得股東批准。
Hansoh Pharma Group Limited announced on June 27, 2024 that it granted a total of 11,397,590 restricted share units to 616 grantees under the restricted share unit plan adopted on May 27, 2019. This includes two company directors, Ms. Sun Yuan who was granted 1,300,000 shares and Dr. Lui Aifeng who was granted 291,850 shares, as well as 614 company employees. The purchase price of the restricted share units was HK$3.379 per share, and the closing price on the date of grant was HK$16.48 per share. The vesting period of the restricted share units is three years and includes performance targets and clawback mechanisms. This plan does not involve the issuance of new shares and does not require shareholder approval.
Hansoh Pharma Group Limited announced on June 27, 2024 that it granted a total of 11,397,590 restricted share units to 616 grantees under the restricted share unit plan adopted on May 27, 2019. This includes two company directors, Ms. Sun Yuan who was granted 1,300,000 shares and Dr. Lui Aifeng who was granted 291,850 shares, as well as 614 company employees. The purchase price of the restricted share units was HK$3.379 per share, and the closing price on the date of grant was HK$16.48 per share. The vesting period of the restricted share units is three years and includes performance targets and clawback mechanisms. This plan does not involve the issuance of new shares and does not require shareholder approval.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more